Both in Pharmaceuticals
Neuphoria Therapeutics vs Propanc Biopharma
Over the past year NEUP returned −29.4% and PPCB returned −99.3%; their daily moves had a correlation of -0.07.
NEUP −29.4% PPCB −99.3%Growth of $1, one year, split-adjusted
| Metric | NEUP | PPCB |
|---|---|---|
| Price | $2.98 | $1.79 |
| Market cap | $16.1M | $1.8M |
| Today | −0.33% | +4.68% |
| 1 month | −13.6% | −63.6% |
| 6 months | −44.6% | −92.9% |
| Year to date | −23.2% | −98.7% |
| 1 year | −32.0% | −99.4% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | — | $832.0K |
| Dividend yield | — | — |
| Volatility (60d) | 27.6% | 730.0% |
| Short % of float | 0.1% | 0.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).